| |
EU Approves Schering-Plough's Hepatitis C Treatment For Patients Co-infected With HIV
|
| |
| |
6/25/2007 2:26:08 AM Monday, Schering-Plough Corp. (SGP) said the European Commission approved the expanded use of its combination therapy in the treatment of previously untreated chronic hepatitis C in patients, who are co-infected with clinically stable HIV. The treatment, which combines PEGINTRON and REBETOL, has already been approved in the EU for treating chronic hepatitis C alone.
The World Health Organization estimates that about 40% of the estimated 2.5 million people living with HIV in Europe are co-infected with the hepatitis C virus (HCV).
In two clinical studies, the PEGINTRON combination therapy achieved higher statistically significant sustained virological response in HCV/HIV co-infected patients compared to conventional therapy, the company noted.
More importantly, the PEGINTRON combination therapy demonstrated a predictable response in patients, signaling that patients with hepatitis C who fail to achieve an early virological response can have their therapy stopped, according to the company.
|
|
| |
| |
|
|
|
